Kinesin-5 Blocker Monastrol Protects Against Bortezomib-Induced Peripheral Neurotoxicity

Area of Science:

• Neuroscience
• Pharmacology
• Oncology

Background:

• Bortezomib treatment can cause neurotoxicity, potentially due to impaired axonal transport.
• Monastrol, a kinesin-5 inhibitor, is known to enhance axonal transport and promote neuronal regeneration.

Purpose of the Study:

• To investigate the neuroprotective potential of monastrol against bortezomib-induced neurotoxicity.
• To assess if monastrol interferes with the anti-cancer effects of bortezomib.

Main Methods:

• Bortezomib was administered to C57BL/6 mice to induce neuropathy.
• Monastrol was administered to evaluate its effect on neuropathy and axonal integrity.
• Cytotoxicity assays were performed on leukemia and multiple myeloma cell lines to assess drug interactions.

Main Results:

• Bortezomib treatment resulted in length-dependent sensory neuropathy with axonal atrophy and fiber loss.
• Monastrol administration significantly reduced axonal injury and improved functional sensory measures.
• Monastrol did not interfere with the cytostatic effects of bortezomib in cancer cell lines.

Conclusions:

• Targeting microtubule turnover with monastrol offers protection against bortezomib-induced neurotoxicity.
• Monastrol's favorable safety profile suggests its potential as a neuroprotective agent in combination chemotherapy.